Bristol-Myers Squibb Articles
Solvay sees dip in 2004 pharma sales
7 March 2005
2004 "best-year in history" at Merck KGaA
21 February 2005
Japan stock market week to February 14
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
SAFE biopharma digital identity standard move
21 February 2005
Gilead reports 48-wk data from HIV study
14 February 2005
BioImage licenses Redistribution to Boeh Ingelheim
14 February 2005
Hitch for Pennsylvania drug pricing suit
14 February 2005
Editor's views on US profit repatriation, re-importation
7 February 2005
Stock Commentary - Europe
7 February 2005
Flamel and B-MS settle terms of Basulin deal
7 February 2005
Higher ulcer risk from Plavix, study shows
31 January 2005
B-MS and Medarex deal becomes effective
24 January 2005
B-MS confirms plans to dispose of OTCs
17 January 2005
Industry cuts 275+ Rx prices for US uninsured under expanded Together Rx Access plan
17 January 2005
B-MS and Otsuka introduce Abilify 5mg
17 January 2005
B-MS and Otsuka's Abilify oral solution approved by FDA
10 January 2005
Bristol-Myers Squibb in talks to sell analgesics business?
10 January 2005
UPDATE: B-MS submits muraglitazar in the USA
10 January 2005
B-MS submits muraglitazar in the USA
10 January 2005
B-MS and Somerset in Emsam distribution deal
10 January 2005
FDA OKs Ranbaxy's generic fosinopril
10 January 2005
B-MS and Gilead set up JV to market triple AIDS drugs
10 January 2005
Stock Commentary - New York
20 December 2004
B-MS sells OYN to One Equity Partners
20 December 2004
B-MS seeks clearance for Pravachol OTC
20 December 2004
Corgentech/B-MS' edifoligide fails in trial
13 December 2004
B-MS launches home test for blood sugar
13 December 2004
BMS-354825 could be challenge to Gleevec?
13 December 2004
Different rationales drive choice for antidiabetics
13 December 2004
Stock Commentary - New York
15 November 2004
B-MS and Medarex in up to $480M alliance
15 November 2004
Eisai 1st-half sales on target, rising 5.3%
15 November 2004
Elliott Sigal confirmed as B-MS Pharma Res Inst president
8 November 2004
Eisai regains rights to antifungal from B-MS
8 November 2004
Stock Commentary - New York
1 November 2004
OBITUARY: BMS announce sudden death of James Palmer
1 November 2004
French Rx R&D losing ground, says Academy
1 November 2004
Stock Commentary - New York
25 October 2004
APP gets FDA OK for generic Paraplatin
25 October 2004
World drug sales up 8% in year to August 2004
25 October 2004
Forest appoints Francis Perier as senior vice president, finance
11 October 2004
B-MS/Otsuka's Abilify gets OK for new use
11 October 2004
Hollis-Eden names Steven Gordziel VP, product development
4 October 2004
Generics battering Sankyo's home sales
4 October 2004
BMS terminates insulin deal with Flamel
27 September 2004
NeoPharm regains oncology products
27 September 2004
Statins to open door for more US OTC switches?
20 September 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
Stock Commentary - New York
6 September 2004
Sanofi posts strong first-half results
6 September 2004
Pharma again tops US charitable list
16 August 2004
Sankyo sales down but profits leap 60%
9 August 2004
Bristol-Myers Squibb reaches $300M deal in SEC litigation; reports 42% 2nd-qtr earnings drop
9 August 2004
Plavix with low-dose aspirin in ACS: NICE
2 August 2004
FDA OK for Par Pharma's generic Mycostatin
2 August 2004
Florida to end pharma disease programs
2 August 2004
Sanofi beats forecasts: 2nd-qtr sales up 19.4%
26 July 2004
Cipla patents Triomune in South Africa
19 July 2004
MSF calls for generic 2nd-line ARV combos
19 July 2004
B-MS HIV/AIDS initiative: preliminary reports
19 July 2004
FDA set to speed US Rx-OTC switches?
12 July 2004
Who suffers least if US Rx price pressure grows?
12 July 2004
US branded drug prices "rose faster after MMA"
12 July 2004
Erbitux cleared by EC for colorectal cancer
5 July 2004
B-MS expects to raise legal reserves by $40M
5 July 2004
New use in EU for Roche's Herceptin
28 June 2004
B-MS and Otsuka's Abilify launched in EU
28 June 2004
Tokyo pharma stocks - week to june 14
21 June 2004
B-MS and Otsuka's Abilify approved in EU
14 June 2004
Sankyo's full-year revenues rise 4.6%
7 June 2004
Pharma "funding phony groups in California"
31 May 2004
Tokyo pharma stocks - week to May 24
31 May 2004
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
